COVID-19 pandemic
Pfizer and its German partner BioNTech begin a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine for adults under the age of 55 years.
Sources: NPR
Changes
- Pfizer and and its German partner BioNTech begins a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine for adults aged up to 55 years.
- Pfizer and its German partner BioNTech begin a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine for adults under the age of 55 years.